Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1611-1617

  Henriksson, Kenneth ^a   From, Jesper ^b   Stratelis, Georgios ^b  

^a AstraZeneca Nordic Baltic ^*  (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Gastroprotection; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Patient adherence; Proton pump inhibitors; Self reported questionnaires

Indexed keywords

DICLOFENAC; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; OSTEOARTHRITIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STOMACH PROTECTION;

EID: 84936936795     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S70651     Document Type: Article

References (32)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;4:487-497.
2. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
3. World Health Organization. Adherence to long-term therapies. 2003. Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed April 29, 2014.
4. Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol. 1981;8:931-936.
5. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013;87:766-772.
6. Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep. 2013;15:300.
7. Rodriguez-Monguio R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003;21:623-650.
8. Henriksson AE, Svensson JO. Upper gastrointestinal bleeding. With special reference to blood transfusion. Eur J Surg. 1991;157:193-196.
9. Ohmann C, Thon K, Hengels KJ, Imhof M. Incidence and pattern of peptic ulcer bleeding in a defined geographical area. DUSUK Study Group. Scand J Gastroenterol. 1992;27:571-581.
10. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ. 1995;311:222-226.
11. Vreeburg EM, Snel P, de Bruijne JW, Bartelsman JF, Rauws EA, Tytgat GN. Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol. 1997;92:236-243.
12. Vonkeman HE, Klok RM, Postma MJ, Brouwers JR, van de Laar MA. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging. 2007;4:681-690.
13. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32:401-413.
14. Swedish National Board of Health and Welfare. Nationella riktlinjer för rörelseorganens sjukdomar. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit [National guidelines for diseases in musculoskeletal organs. Osteoporosis, arthrosis, inflammatory back disease and ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis]. 2012. Available from: http://www.socialstyrelsen.se/nationellariktlinjerforrorelseorganenssjukdomar/Documents/nr-rorelseorganen-vetenskapligtunderlag.pdf. Accessed April 29, 2014. Swedish.
15. National Institute for Health and Care Excellence. The care and management of osteoarthritis in adults. Clinical guidelines CG59 issued February 2008, replaced by CG177 Osteoarthritis. Available from: http://www.nice.org.uk/guidance/CG177. Accessed April 29, 2014.
16. de Jong HJ, Korevaar JC, van Dijk L, Voogd E, van Dijk CE, van Oijen MG. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open. 2013;3(7).
17. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009;25:195-204.
18. Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2008;28:97-106.
19. Jonasson C, Hatlebakk JG, Lundell L, Kouri JP, Andersen M, Granath F. Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. Eur J Gastroenterol Hepatol. 2013;25:531-538.
20. van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26:265-275.
21. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: is there a problem? Eur J Pain. 2009;13(2):115-123.
22. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213-224.
23. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-434.
24. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on non-steroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol. 2006;4:1337-1345.
25. Lanas A, Polo-Tomás M, Roncales P, Gonzalez MA, Zapardiel J. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol. 2012;107:707-714.
26. Valkhoff VE, van Soest EM, Mazzaglia G, et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study. Arthritis Rheum. 2012;64:2792-2802.
27. van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011;60:1650-1659.
28. Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr. Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol. 2011;64:250-254.
29. de Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol. 2010;5:313-326.
30. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28:1097-1107.
31. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527-539.
32. Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18:1137-1147.